Edition:
United Kingdom

Rxi Pharmaceuticals Corp (RXII.OQ)

RXII.OQ on NASDAQ Stock Exchange Capital Market

1.24USD
19 Sep 2018
Change (% chg)

$0.04 (+3.33%)
Prev Close
$1.20
Open
$1.19
Day's High
$1.27
Day's Low
$1.19
Volume
9,847
Avg. Vol
55,532
52-wk High
$7.60
52-wk Low
$1.18

Latest Key Developments (Source: Significant Developments)

Rxi Pharmaceuticals Announces Positive Results From Phase 1/2 Trial With Rxi-109 For Retinal Scarring
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Rxi Pharmaceuticals Corp ::RXI PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM PHASE 1/2 TRIAL WITH RXI-109 FOR RETINAL SCARRING.RXI PHARMACEUTICALS - STUDY SUCCESSFULLY MEETS PRIMARY OBJECTIVE BY SHOWING THAT RXI-109 IS SAFE AND WELL TOLERATED IN THIS DOSE ESCALATION STUDY.RXI PHARMACEUTICALS CORP - RXI-109 MEETS SECONDARY OBJECTIVES WITH IMPROVED OR STABLE DISEASE IN STUDY EYES.  Full Article

Rxi Pharmaceuticals Announces Positive Results From Phase 2 Trial With Samcyprone For Treatment Of Common Warts
Friday, 18 May 2018 

May 18 (Reuters) - Rxi Pharmaceuticals Corp ::RXI PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL WITH SAMCYPRONE™ FOR THE TREATMENT OF COMMON WARTS.RXI PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL WITH SAMCYPRONE™ FOR THE TREATMENT OF COMMON WARTS.RXI PHARMACEUTICALS CORP - STUDY SUCCESSFULLY MEETS ITS PRIMARY EFFECTIVENESS OBJECTIVES AND ITS SECONDARY SAFETY AND TOLERABILITY OBJECTIVES.RXI PHARMACEUTICALS CORP - STUDY RESULTS SHOW THAT SAMCYPRONE WAS SAFE AND WELL TOLERATED.  Full Article

RXI Pharmaceuticals Says Selling Stockholders Are Offering On A Resale Basis An Aggregate Of 1.2 Million Shares Of Co's Common Stock
Wednesday, 9 May 2018 

May 9 (Reuters) - RXI Pharmaceuticals Corp ::RXI PHARMACEUTICALS CORP SAYS SELLING STOCKHOLDERS ARE OFFERING ON A RESALE BASIS AN AGGREGATE OF 1.2 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING.  Full Article

RXi Pharmaceuticals Announces Grant Of Patent From USPTO For sd-rxRNAs To Treat Fibrotic Disorders
Tuesday, 8 May 2018 

May 8 (Reuters) - Rxi Pharmaceuticals Corp ::RXI PHARMACEUTICALS - GRANTED PATENT FROM USPTO FOR METHODS OF USE OF SD-RXRNAS TARGETING CONNECTIVE TISSUE GROWTH FACTOR TO TREAT FIBROTIC DISORDERS.  Full Article

Rxi Pharmaceuticals Files For Mixed Shelf Of Upto $100 Million
Thursday, 29 Mar 2018 

March 29 (Reuters) - Rxi Pharmaceuticals Corp ::RXI PHARMACEUTICALS CORP FILES FOR MIXED SHELF OF UPTO $100 MILLION - SEC FILING.  Full Article

RXI Says Determined Interim Financial Statements For Qtrs Ended March 31, June 30, Sept 30, 2017 Should No Longer Be Relied Upon‍​
Monday, 26 Mar 2018 

March 26 (Reuters) - Rxi Pharmaceuticals Corp ::RXI - ON MARCH 20, DETERMINED INTERIM FINANCIAL STATEMENTS FOR QTRS ENDED MARCH 31, JUNE 30, AND SEPT 30, 2017 SHOULD NO LONGER BE RELIED UPON‍​.RXI PHARMACEUTICALS - ‍ADJUSTMENT IN RESTATED INTERIM FINANCIAL STATEMENTS FOR PRIOR PERIODS IS A NON-CASH CHARGE​.RXI - ‍ADJUSTMENT IN RESTATED STATEMENTS DID NOT AFFECT PREVIOUSLY REPORTED NET LOSS/OPERATING CASH FLOWS, HAD NO IMPACT ON BALANCE SHEET​.RXI - CONCLUDED INTERNAL CONTROL DEFICIENCIES SPECIFIC TO ISSUE REPRESENT 'MATERIAL WEAKNESS' IN INTERNAL CONTROL OVER FINANCIAL REPORTING​.RXI - DETERMINED CO'S DISCLOSURE CONTROLS & PROCEDURES WERE NOT EFFECTIVE FOR PRIOR PERIODS​.  Full Article

RXi Pharmaceuticals Announces Business Strategy To Focus On Immuno-Oncology Programs To Accelerate Growth
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Rxi Pharmaceuticals Corp ::RXI PHARMACEUTICALS ANNOUNCES BUSINESS STRATEGY TO FOCUS ON IMMUNO-ONCOLOGY PROGRAMS TO ACCELERATE GROWTH.RXI PHARMACEUTICALS CORP - COMPANY TO "CAPITALIZE" ON PROPRIETARY SELF-DELIVERING RNAI PLATFORM (SD-RXRNA).RXI PHARMACEUTICALS CORP - 2018 BUSINESS STRATEGY INCLUDES DEVELOPING IMMUNO-ONCOLOGY TARGETS BEYOND CHECKPOINT INHIBITION, I.E. CELL DIFFERENTIATION.RXI PHARMACEUTICALS- RELATING TO OPERATIONAL REVIEW, RXI INTENDS TO PARTNER/OUT-LICENSE BOTH ITS DERMATOLOGY AND OPHTHALMOLOGY FRANCHISES.  Full Article

RXi Pharmaceuticals Announces Reverse Stock Split
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Rxi Pharmaceuticals Corp ::RXI PHARMACEUTICALS CORP - ANNOUNCED A REVERSE STOCK SPLIT OF ITS SHARES OF COMMON STOCK AT A RATIO OF 1-FOR-10.RXI PHARMACEUTICALS CORP - REVERSE STOCK SPLIT WILL BECOME EFFECTIVE AT 12:01 A.M. EASTERN TIME ON JANUARY 8, 2018.RXI PHARMACEUTICALS ANNOUNCES REVERSE STOCK SPLIT.  Full Article

RXi Pharma Announces Meets Secondary Objective With RXI-109 For Dermal Scarring
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Rxi Pharmaceuticals Corp ::RXI PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL WITH RXI-109 FOR DERMAL SCARRING.RXI PHARMACEUTICALS CORP - RXI-109 MEETS SECONDARY OBJECTIVE AS IT WAS SHOWN TO BE SAFE AND WELL TOLERATED.RXI PHARMACEUTICALS CORP -RXI-109 STUDY SUCCESSFULLY MEETS PRIMARY EFFECTIVENESS OBJECTIVE WITH STATISTICALLY SIGNIFICANT OUTCOMES.RXI PHARMACEUTICALS - FULL STUDY RESULTS SHOW RXI-109 WAS SAFE, WELL TOLERATED FOR ALL DOSAGE GROUPS.  Full Article

RXi Pharma and Gustave Roussy have entered into a collaborative research agreement​
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Rxi Pharmaceuticals Corp :RXi Pharmaceuticals Corp - ‍co, Gustave Roussy announced that they have entered into a collaborative research agreement​.RXi Pharmaceuticals - ‍collaborative research agreement to evaluate potential of RXi's sd-rxRNA technology platform for use in cancer treatments​.  Full Article

BRIEF-Rxi Pharmaceuticals Announces Positive Results From Phase 2 Trial With Samcyprone For Treatment Of Common Warts

* RXI PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL WITH SAMCYPRONE™ FOR THE TREATMENT OF COMMON WARTS